1. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. (May 2020) Authors: Klück, Viola; Jansen, Tim L Th A; Janssen, Matthijs; Comarniceanu, Antoaneta; Efdé, Monique; Tengesdal, Isak W; Schraa, Kiki; Cleophas, Maartje C P; Scribner, Curtis L; Skouras, Damaris B; Marchetti, Carlo; Dinarello, Charles A; Joosten, Leo A B Journal: Lancet Issue: Volume 2:Number 5(2020) Page Start: e270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗